Naratriptan Tablet
NDC Package 87063-287-12

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.Limitations of Use:Use only if a clear diagnosis of migraine has been established. This formulation utilizes a tablet delivery system. Marketed by Asclemed Usa Inc., this product is identified by NDC 87063-287 and is authorized under FDA application ANDA200502.

Identification & Billing

NDC Package Code
87063-287-12
Package Description
12 TABLET in 1 BOTTLE
Product Code
87063-287
11-Digit Billing Format
87063028712

Clinical Specifications

Proprietary Name
Naratriptan
Non-Proprietary Name
Naratriptan
Substance Name
Naratriptan Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
NARATRIPTAN HYDROCHLORIDE 1 mg/1
Pharmacologic Class
Usage Information
Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.Limitations of Use:Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks.Naratriptan tablets are not indicated for the prevention of migraine attacks.Safety and effectiveness of naratriptan tablets have not been established for cluster headache.

Regulatory & Marketing

Labeler Name
Asclemed Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA200502
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-15-2011
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (87063-287). Click a package code to view its specific billing and regulatory data.

87063-287-09
9 TABLET in 1 BLISTER PACK
87063-287-30
30 TABLET in 1 BOTTLE
87063-287-60
60 TABLET in 1 BOTTLE
87063-287-90
90 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 87063-287-12 identifies a specific commercial package of 12 tablet in 1 bottle of Naratriptan, a human prescription drug labeled by Asclemed Usa Inc.. This tablet is formulated for oral use and contains naratriptan hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Asclemed Usa Inc. on March 15, 2011. The current certification is valid through December 31, 2027.

How is this Asclemed Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 87063028712. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
87063-287-12
11-Digit CMS (5-4-2)
87063-0287-12

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.